A secretagogue is anything that triggers secretion; a growth-hormone secretagogue stimulates the growth-hormone axis, prompting the body to release more of its own growth hormone1. The whole category splits cleanly into two families defined by which receptor they engage.
In plain terms: these are "nudge" compounds — instead of adding growth hormone directly, they ask the body to make more of its own.
The two families
| Family | Mimics | Receptor | Examples |
|---|---|---|---|
| GHRH analogs | Growth-hormone-releasing hormone | GHRH receptor | Sermorelin, CJC-1295, tesamorelin |
| Ghrelin / GHS agonists | Ghrelin | Ghrelin (GHS) receptor | Ipamorelin, GHRP-6, GHRP-2 |
- GHRH analogs activate the GHRH receptor — one lever on the axis1. Within this family, differences are mostly about half-life and stabilisation (sermorelin vs CJC-1295 vs ipamorelin, tesamorelin vs CJC-1295).
- GHS agonists activate the ghrelin receptor — a different lever1. Within this family, differences are mostly about selectivity (ipamorelin vs GHRP-6 vs GHRP-2).
Why the two are paired
Because the families pull two different levers on the same axis, they are studied together as complementary mechanisms — the reason CJC-1295 and ipamorelin are the archetypal pairing. In plain terms: pressing two different "release" buttons at once is the logic behind combining a GHRH analog with a GHS agonist.
The honest evidence note
A review of this class found the compounds are generally well tolerated in the studies done, but flagged that the evidence is limited and uneven, with signals such as reduced insulin sensitivity worth noting1. Most of these compounds are research-only, not approved medicines, and human data vary widely from one to the next.
The map in one sentence
If a compound "mimics GHRH," it is in the first family; if it "acts on the ghrelin/GHS receptor," it is in the second — and that single distinction organises the entire category.
This is an educational overview of a mechanism category, not medical advice or an endorsement of any compound.